Drug and Biologic Therapeutic Delivery – DBTD

Topics

• Delivery of therapeutic-based molecules, biologics, hybrids, drug combinations, vaccines (non-mRNA), novel viruses, VLPs (Virus Like Particles), antibiotics, antivirals, antigens, and cell therapies.
• Studies utilizing controlled or triggered release, intraorgan, and intracellular delivery.
• Targeted strategies using peptides, lipids, carbohydrates. Delivery strategies including light and physical methods, antibiotics, and antivirals.
• Delivery vehicles including viruses, liposomes, micelles, vesicles, nanoparticles, biomaterials, and cells. 
• Studies of the biological barriers to delivery (e.g., membrane, tissue, cellular, trafficking, physical). Including the blood-brain barrier.
• Studies of the interactions of delivery vehicles, devices, and/or payloads with the immune system and host-tissue. 
• AI & ML approaches in preclinical drug delivery vehicle design.

Shared Interests and Overlaps

There are shared interests in nanomaterials and nanosystems towards biomedical applications with Innovations in Nanosystems and Nanotechnology (INN). Applications that focus on the targeted delivery, use as vehicles, and controlled release, of these nanostructures as therapeutic strategies are reviewed in DBTD. Applications that focus on the unique features of multifunctional nanoparticles as well as the design, synthesis, and development of nanostructures, engineered exosomes, protein-based materials, and theranostics are reviewed in INN.

There are shared interests in gene and drug delivery with Biomaterials and Biointerfaces (BMBI). Applications that focus more on the design and development of novel delivery vehicles, vectors, or payloads are reviewed in DBTD. Applications that focus on biocompatibility of delivery vehicles or delivery from implants are reviewed in BMBI.

There are shared interests in delivery with BBBT (81).  Applications that focus on fundamental aspects of therapeutic delivery of cargoes of synthetic and biologic nature except nucleic acids are reviewed in DBTD. Applications that focus on fundamental aspects of nucleic acid delivery, including intracellular delivery, delivery vehicle development, targeting strategies, and overcoming biological barriers are reviewed in BBBT (81). 

There are shared interests in gene and drug-delivery strategies with Advancing Therapeutics A (ATA). Applications that focus on foundational technological advancements, preclinical evaluation of drug and biologics delivery strategies or are focused on bioengineering principles may be assigned to DBTD. Applications that focus on efficacy, safety, or toxicity in animal models, or pilot clinical trials for neoplastic diseases may be assigned to ATA. 

There are shared interests in gene and drug-delivery strategies for non-cancer related diseases with Advancing Therapeutics B (ATB). Applications that focus on foundational technological advancements, preclinical evaluation of drug and biologics delivery strategies or are focused on bioengineering principles may be assigned to DBTD. Applications that emphasize treatment efficacy, safety, or toxicity in animal models or pilot clinical trials for non-cancer related are reviewed in ATB 

There are shared interests in development of polymeric, supramolecular and nanomaterials with Chemical Synthesis & Biosynthesis (CSB). Applications that emphasize development of higher-level nanostructures, nanodevices, nano-biologics, or biomaterials customized for specific drug or biologic agent delivery are reviewed in DBTD. Applications that emphasize new basic synthetic chemistry strategies are reviewed in CSB.

There are shared interests in involving agents for therapeutic delivery with Drug and Biologic Disposition and Toxicity (DBDT). Applications that involve fundamental aspects of therapeutic delivery, including controlled or triggered release, intraorgan/intracellular delivery, delivery vehicle development, or targeting strategies are reviewed in DBTD. Applications that focus on the disposition and safety of delivery agents are reviewed in DBDT.